Rhythm Pharmaceuticals (RYTM) Stock Statistics & Valuation Metrics

Rhythm Pharmaceuticals has a market cap or net worth of $5.73B. The enterprise value is $5.58B.

Rhythm Pharmaceuticals has 65,680,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Rhythm Pharmaceuticals’s return on equity (ROE) is -11.99 and return on invested capital (ROIC) is -96.06%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Rhythm Pharmaceuticals had revenue of 130.13M and earned -260.60M in profits. Earnings per share was -4.21.

In the last 12 months, operating cash flow was -113.49M and capital expenditures 40.00M, giving a free cash flow of -73.49M billion.

Rhythm Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Rhythm Pharmaceuticals upcoming earnings date is Aug 5, 2025, TBA (Confirmed).

Rhythm Pharmaceuticals as a current ratio of 3.24, with Debt / Equity ratio of 2.49%

In the past 12 months, Rhythm Pharmaceuticals has paid 346.00K in taxes.

Rhythm Pharmaceuticals EV to EBITDA ratio is -13.98, with an EV/FCF ratio of -29.24.

Rhythm Pharmaceuticals has $314.49M in cash and marketable securities with $4.06M in debt, giving a net cash position of -$310.43M billion.

Gross margin is 89.49%, with operating margin of -204.04%, and net profit margin of -200.27%.

The average price target for Rhythm Pharmaceuticals is $104.21, which is 11.43% higher than the current price. The consensus rating is Strong Buy